Fig. 5: Administration of AAV9-hNdufs6 could not reverse cardiac dysfunction in adult Ndufs6gt/gt cardiomyopathy mice.
From: Gene therapy prevents onset of mitochondrial cardiomyopathy in neonatal mice with Ndufs6 deficiency
A Schematic diagram of gene therapy for adult Ndufs6gt/gt mice. B Representative M-mode echocardiograms and quantification of left ventricular EF% (*p = 0.0134) and FS% (*p = 0.0222) (n = 7). C Running time of treadmill exercise tolerance test for WT, Ndufs6gt/gt, and AAV-Adult groups (n = 7). D Quantification of LVEDD for WT, Ndufs6gt/gt, and AAV-Adult groups (***p = 0.0001) (n = 6). E Quantification of HW/BW for WT, Ndufs6gt/gt, and AAV-Adult groups (*p = 0.0377) (n = 6). F Representative images of Masson’s trichrome staining and measurement of fibrosis (n = 4). Scale bar = 100 μm. G Representative images of TUNEL staining for apoptosis and quantification analysis of cardiomyocytes from WT, Ndufs6gt/gt, and AAV-Adult mice (n = 4). Scale bar = 50 μm. The tissue slides utilized are consecutive sections from the same specimen stained with Masson’s trichrome on (F).
